The Olo system [Image courtesy of Sight Diagnostics]
Blood diagnostic testing developer Sight Diagnostics announced this week that it raised $71 million in a Series D financing round.Koch Disruptive Technologies, Longliv Ventures and OurCrowd participated in the round, bringing Sight Diagnostics’ total funding to more than $124 million, according to a news release.
Tel Aviv, Israel-based Sight Diagnostics said the funding will support its commercial operations around the world while also advancing its R&D into the detection of new diseases, as well as the blood factors affecting the severity of COVID-19.
“This new investment will enable Sight to substantially expand our U.S. footprint and help usher in a new era of AI-driven diagnostics for a myriad of diseases and health conditions,” Sight Diagnostics CEO & co-founder Yossi Pollak said in the release. “We’re glad to have Koch Disrup…